TG Therapeutics (NASDAQ:TGTX) Earns Hold (C-) Rating from Weiss Ratings

TG Therapeutics (NASDAQ:TGTX)‘s stock had its “hold (c-)” rating reiterated by equities researchers at Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.

TGTX has been the subject of several other research reports. B. Riley boosted their price target on shares of TG Therapeutics from $53.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, September 17th. The Goldman Sachs Group upgraded shares of TG Therapeutics to a “hold” rating and set a $37.00 price target for the company in a report on Thursday, July 10th. Finally, HC Wainwright began coverage on shares of TG Therapeutics in a research report on Monday, October 6th. They issued a “buy” rating and a $60.00 price objective on the stock. Four analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $49.00.

TG Therapeutics Trading Down 0.5%

NASDAQ:TGTX opened at $33.33 on Friday. TG Therapeutics has a one year low of $22.92 and a one year high of $46.48. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. The firm has a market cap of $5.29 billion, a P/E ratio of 90.08 and a beta of 1.97. The firm has a 50-day simple moving average of $32.87 and a 200-day simple moving average of $34.94.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.15). TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The business had revenue of $141.15 million during the quarter, compared to the consensus estimate of $147.76 million. During the same quarter in the prior year, the firm posted $0.04 EPS. The company’s revenue for the quarter was up 92.1% compared to the same quarter last year. TG Therapeutics has set its FY 2025 guidance at EPS. Equities analysts anticipate that TG Therapeutics will post 0.08 EPS for the current fiscal year.

Insider Activity

In other news, Director Sagar Lonial sold 20,852 shares of TG Therapeutics stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $32.24, for a total value of $672,268.48. Following the transaction, the director owned 94,061 shares of the company’s stock, valued at $3,032,526.64. The trade was a 18.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 10.64% of the stock is currently owned by insiders.

Institutional Trading of TG Therapeutics

Large investors have recently bought and sold shares of the stock. Johnson Financial Group Inc. purchased a new stake in TG Therapeutics during the 2nd quarter worth approximately $25,000. Ameritas Advisory Services LLC purchased a new stake in TG Therapeutics during the 2nd quarter worth approximately $25,000. Golden State Wealth Management LLC grew its position in TG Therapeutics by 100.0% during the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 433 shares during the last quarter. Salomon & Ludwin LLC purchased a new stake in TG Therapeutics during the 3rd quarter worth approximately $34,000. Finally, SVB Wealth LLC purchased a new stake in TG Therapeutics during the 1st quarter worth approximately $37,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.